SEC Form 4 · accession 0001587221-17-000016
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
John Peter Walker
Officer — Interim CEO · Director
Period of report
May 24, 2017
Accepted (ET)
May 25, 2017 · 8:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 24, 2017 | P | 36,166 | $1.3425 | A | 169,344 | D | |
| Common StockF2 | May 25, 2017 | P | 37,550 | $1.3672 | A | 206,894 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.35, inclusive. The reporting person undertakes to provide to Zosano Pharma Corporation, any security holder of Zosano Pharma Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.34 to $1.38, inclusive. The reporting person undertakes to provide to Zosano Pharma Corporation, any security holder of Zosano Pharma Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.